Pharmafile Logo
Pharmafocus logo
Advanced Search

ASCO

Showing 15 posts of 56 posts found.

Pfizer breast cancer trial stopped following promising results

April 15, 2015
Sales and Marketing ASCO, FDA, Pfizer, ibrance, palbociclib

Regulators have stopped a Phase III clinical trial of Pfizer’s Ibrance early after it demonstrated improved survival in women with …

News
Merck logo

Merck and Advaxis team up on immuno-oncology

August 26, 2014
Manufacturing and Production, Medical Communications, Research and Development ASCO, Merck, immunology, pd-1, pembrolizumab

Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …

News
Merck image

PD-1 cancer race heats up as Merck takes lead

July 2, 2014
Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab

Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …

News
ASCO image

Value tops the agenda at ASCO cancer conference

June 30, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Cancer, chicago, mccafferty, oncology

The annual American Society of Clinical Oncology (ASCO) meeting has long been one of the most important events on the …

Feature
BMS image

New BMS cancer treatment shines

June 25, 2014
Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab

Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …

News

Merck drug shines at ASCO

June 4, 2014
Research and Development, Sales and Marketing ASCO, Cancer, FDA, MK-3475, Merck, melanoma

Merck has shown off one of its investigative cancer drug’s impressive results in advanced head and neck cancer at ASCO …

News
boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

News

ASCO 2014: old dogs, new tricks top the bill

June 2, 2014
Research and Development, Sales and Marketing ASCO, Cancer, chicago, docetaxel, exemestane

 Research showing the effectiveness of established cancer treatments in new settings is taking centre stage at this year’s American Society …

News
BMS image

BMS signs cancer deal

May 28, 2014
Research and Development, Sales and Marketing ASCO, AstraZeneca, BMS, Cancer, Merck, Roche, cytomx, oncology

Bristol-Myers Squibb has partnered with CytomX Therapeutics to discover and develop new immuno-oncology candidates using the latter’s Probody Platform technology. …

News
roche_logo_shadow_7

Roche gets oncology boost with cancer vaccine

May 16, 2014
Research and Development, Sales and Marketing ASCO, Roche, bladder cancer, oncology

Roche’s most advanced experimental cancer immunotherapy has had impressive results in a small Phase I trial, reducing tumour size in …

News

ASCO 2014: Cancer immune therapy race heats up

May 15, 2014
2014, ASCO, AZ, BMS, Cancer, Merck, Roche, chicago

A number of major players in oncology are set to showcase rival immunotherapy data at this year’s American Society of …

News
AZ image

AstraZeneca lung cancer data reveals promise

May 15, 2014
Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer

AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …

News

US cancer docs warn of rising drug prices

May 7, 2014
Research and Development, Sales and Marketing ASCO, Cancer, NICE, Obama, US, United States, republicans

American cancer doctors are warning that the rising price of oncology medicines is making it unaffordable for the country’s healthcare …

News

ASCO: Dispatches from the frontline against cancer

July 22, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, McConaghie

The growing promise of pharma’s immunotherapy pipeline for cancer was undoubtedly the hottest topic at this year’s ASCO conference. The …

Feature

Novartis drug shows cancer promise

June 5, 2013
Research and Development, Sales and Marketing ASCO, Cancer, Novartis

A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …

News

Latest content

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023